Development of the clinical candidate PBD-C06, a humanized pGlu3-Aβ-specific antibody against Alzheimer's disease with reduced complement activation (Q89866273)

From Wikidata

Jump to navigation Jump to search

scientific article published on 24 February 2020

Language	Label	Description	Also known as
English	Development of the clinical candidate PBD-C06, a humanized pGlu3-Aβ-specific antibody against Alzheimer's disease with reduced complement activation	scientific article published on 24 February 2020

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32094456 AND SRC:MED&resulttype=core&format=json

9 April 2020

Development of the clinical candidate PBD-C06, a humanized pGlu3-Aβ-specific antibody against Alzheimer's disease with reduced complement activation (English)

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32094456 AND SRC:MED&resulttype=core&format=json

9 April 2020

Cynthia A Lemere

6

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32094456 AND SRC:MED&resulttype=core&format=json

9 April 2020

author name string

Thore Hettmann

1

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32094456 AND SRC:MED&resulttype=core&format=json

9 April 2020

Stephen D Gillies

2

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32094456 AND SRC:MED&resulttype=core&format=json

9 April 2020

Martin Kleinschmidt

3

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32094456 AND SRC:MED&resulttype=core&format=json

9 April 2020

Anke Piechotta

4

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32094456 AND SRC:MED&resulttype=core&format=json

9 April 2020

Koki Makioka

5

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32094456 AND SRC:MED&resulttype=core&format=json

9 April 2020

Stephan Schilling

7

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32094456 AND SRC:MED&resulttype=core&format=json

9 April 2020

Jens-Ulrich Rahfeld

8

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32094456 AND SRC:MED&resulttype=core&format=json

9 April 2020

Inge Lues

9

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32094456 AND SRC:MED&resulttype=core&format=json

9 April 2020

publication date

24 February 2020

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32094456 AND SRC:MED&resulttype=core&format=json

9 April 2020

Scientific Reports

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32094456 AND SRC:MED&resulttype=core&format=json

9 April 2020

10

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32094456 AND SRC:MED&resulttype=core&format=json

9 April 2020

1

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32094456 AND SRC:MED&resulttype=core&format=json

9 April 2020

3294

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32094456 AND SRC:MED&resulttype=core&format=json

9 April 2020

Alzheimer's Disease

1 reference

https://api.crossref.org/works/10.1038/S41598-020-60319-5

7 January 2021

based on heuristic

inferred from DOI database lookup

AChE Inhibitors and NMDA Receptor Antagonists in Advanced Alzheimer's Disease

1 reference

https://api.crossref.org/works/10.1038/S41598-020-60319-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Passive Aβ Immunotherapy: Current Achievements and Future Perspectives

1 reference

https://api.crossref.org/works/10.1038/S41598-020-60319-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Alzheimer's disease drug development pipeline: 2017.

1 reference

https://api.crossref.org/works/10.1038/S41598-020-60319-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Anti-Amyloid-β Monoclonal Antibodies for Alzheimer's Disease: Pitfalls and Promise

1 reference

https://api.crossref.org/works/10.1038/S41598-020-60319-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade

1 reference

https://api.crossref.org/works/10.1038/S41598-020-60319-5

7 January 2021

based on heuristic

inferred from DOI database lookup

The amyloid hypothesis of Alzheimer's disease at 25 years

1 reference

https://api.crossref.org/works/10.1038/S41598-020-60319-5

7 January 2021

based on heuristic

inferred from DOI database lookup

The Amyloid-β Oligomer Hypothesis: Beginning of the Third Decade.

1 reference

https://api.crossref.org/works/10.1038/S41598-020-60319-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study

1 reference

https://api.crossref.org/works/10.1038/S41598-020-60319-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Semagacestat Is a Pseudo-Inhibitor of γ-Secretase

1 reference

https://api.crossref.org/works/10.1038/S41598-020-60319-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease.

1 reference

https://api.crossref.org/works/10.1038/S41598-020-60319-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup

1 reference

https://api.crossref.org/works/10.1038/S41598-020-60319-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Bapineuzumab for mild to moderate Alzheimer's disease in two global, randomized, phase 3 trials

1 reference

https://api.crossref.org/works/10.1038/S41598-020-60319-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease

1 reference

https://api.crossref.org/works/10.1038/S41598-020-60319-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Passive Immunization against Pyroglutamate-3 Amyloid-β Reduces Plaque Burden in Alzheimer-Like Transgenic Mice: A Pilot Study

1 reference

https://api.crossref.org/works/10.1038/S41598-020-60319-5

7 January 2021

based on heuristic

inferred from DOI database lookup

An anti-pyroglutamate-3 Aβ vaccine reduces plaques and improves cognition in APPswe/PS1ΔE9 mice

1 reference

https://api.crossref.org/works/10.1038/S41598-020-60319-5

7 January 2021

based on heuristic

inferred from DOI database lookup

A plaque-specific antibody clears existing β-amyloid plaques in Alzheimer's disease mice

1 reference

https://api.crossref.org/works/10.1038/S41598-020-60319-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Identification of low molecular weight pyroglutamate A{beta} oligomers in Alzheimer disease: a novel tool for therapy and diagnosis

1 reference

https://api.crossref.org/works/10.1038/S41598-020-60319-5

7 January 2021

based on heuristic

inferred from DOI database lookup

High sensitivity analysis of amyloid-beta peptide composition in amyloid deposits from human and PS2APP mouse brain

1 reference

https://api.crossref.org/works/10.1038/S41598-020-60319-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Biochemical stages of amyloid-β peptide aggregation and accumulation in the human brain and their association with symptomatic and pathologically preclinical Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1038/S41598-020-60319-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Glutaminyl cyclase in human cortex: correlation with (pGlu)-amyloid-β load and cognitive decline in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1038/S41598-020-60319-5

7 January 2021

based on heuristic

inferred from DOI database lookup

On the seeding and oligomerization of pGlu-amyloid peptides (in vitro)

1 reference

https://api.crossref.org/works/10.1038/S41598-020-60319-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Intraneuronal pyroglutamate-Abeta 3-42 triggers neurodegeneration and lethal neurological deficits in a transgenic mouse model

1 reference

https://api.crossref.org/works/10.1038/S41598-020-60319-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Pyroglutamate-modified amyloid-β protein demonstrates similar properties in an Alzheimer's disease familial mutant knock-in mouse and Alzheimer's disease brain

1 reference

https://api.crossref.org/works/10.1038/S41598-020-60319-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Pyroglutamate-3 amyloid-β deposition in the brains of humans, non-human primates, canines, and Alzheimer disease-like transgenic mouse models

1 reference

https://api.crossref.org/works/10.1038/S41598-020-60319-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-β.

1 reference

https://api.crossref.org/works/10.1038/S41598-020-60319-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Pyroglutamate formation influences solubility and amyloidogenicity of amyloid peptides

1 reference

https://api.crossref.org/works/10.1038/S41598-020-60319-5

7 January 2021

based on heuristic

inferred from DOI database lookup

N-Terminal pyroglutamate formation of Aβ38 and Aβ40 enforces oligomer formation and potency to disrupt hippocampal long-term potentiation

1 reference

https://api.crossref.org/works/10.1038/S41598-020-60319-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Pyroglutamate Amyloid-β (Aβ): A Hatchet Man in Alzheimer Disease

1 reference

https://api.crossref.org/works/10.1038/S41598-020-60319-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Pyroglutamate-modified amyloid beta-peptides--AbetaN3(pE)--strongly affect cultured neuron and astrocyte survival

1 reference

https://api.crossref.org/works/10.1038/S41598-020-60319-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Glutaminyl cyclase inhibition attenuates pyroglutamate Abeta and Alzheimer's disease-like pathology

1 reference

https://api.crossref.org/works/10.1038/S41598-020-60319-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Glutaminyl Cyclase Inhibitor PQ912 Improves Cognition in Mouse Models of Alzheimer's Disease-Studies on Relation to Effective Target Occupancy

1 reference

https://api.crossref.org/works/10.1038/S41598-020-60319-5

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase 1 study to evaluate the safety and pharmacokinetics of PQ912, a glutaminyl cyclase inhibitor, in healthy subjects.

1 reference

https://api.crossref.org/works/10.1038/S41598-020-60319-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer's disease: results of a randomized, double-blind, placebo-controlled phase 2a study

1 reference

https://api.crossref.org/works/10.1038/S41598-020-60319-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Focusing the amyloid cascade hypothesis on N-truncated Abeta peptides as drug targets against Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1038/S41598-020-60319-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunotherapy targeting pyroglutamate-3 Aβ: prospects and challenges

1 reference

https://api.crossref.org/works/10.1038/S41598-020-60319-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Structural and functional analyses of pyroglutamate-amyloid-β-specific antibodies as a basis for Alzheimer immunotherapy

1 reference

https://api.crossref.org/works/10.1038/S41598-020-60319-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Modified amyloid variants in pathological subgroups of β-amyloidosis

1 reference

https://api.crossref.org/works/10.1038/S41598-020-60319-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Antibody humanization by CDR grafting.

1 reference

https://api.crossref.org/works/10.1038/S41598-020-60319-5

7 January 2021

based on heuristic

inferred from DOI database lookup

RosettaAntibody: antibody variable region homology modeling server

1 reference

https://api.crossref.org/works/10.1038/S41598-020-60319-5

7 January 2021

based on heuristic

inferred from DOI database lookup

An analysis of the sequences of the variable regions of Bence Jones proteins and myeloma light chains and their implications for antibody complementarity

1 reference

https://api.crossref.org/works/10.1038/S41598-020-60319-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Conformations of immunoglobulin hypervariable regions

1 reference

https://api.crossref.org/works/10.1038/S41598-020-60319-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc

1 reference

https://api.crossref.org/works/10.1038/S41598-020-60319-5

7 January 2021

based on heuristic

inferred from DOI database lookup

A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples

1 reference

https://api.crossref.org/works/10.1038/S41598-020-60319-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Impact of amyloid β aggregate maturation on antibody treatment in APP23 mice

1 reference

https://api.crossref.org/works/10.1038/S41598-020-60319-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1038/S41598-020-60319-5

7 January 2021

based on heuristic

inferred from DOI database lookup

The levels of soluble versus insoluble brain Abeta distinguish Alzheimer's disease from normal and pathologic aging

1 reference

https://api.crossref.org/works/10.1038/S41598-020-60319-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1038/S41598-020-60319-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Amyloid beta-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates

1 reference

https://api.crossref.org/works/10.1038/S41598-020-60319-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Diffusible, nonfibrillar ligands derived from Aβ 1–42 are potent central nervous system neurotoxins

1 reference

https://api.crossref.org/works/10.1038/S41598-020-60319-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline

1 reference

https://api.crossref.org/works/10.1038/S41598-020-60319-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Lipids revert inert Abeta amyloid fibrils to neurotoxic protofibrils that affect learning in mice

1 reference

https://api.crossref.org/works/10.1038/S41598-020-60319-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Posttranslational modification impact on the mechanism by which amyloid-β induces synaptic dysfunction.

1 reference

https://api.crossref.org/works/10.1038/S41598-020-60319-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Endogenous amyloid-β is necessary for hippocampal synaptic plasticity and memory

1 reference

https://api.crossref.org/works/10.1038/S41598-020-60319-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Amyloid-β peptide protects against microbial infection in mouse and worm models of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1038/S41598-020-60319-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Aβ-Immunotherapeutic strategies: a wide range of approaches for Alzheimer's disease treatment

1 reference

https://api.crossref.org/works/10.1038/S41598-020-60319-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Effector function of anti-pyroglutamate-3 Aβ antibodies affects cognitive benefit, glial activation and amyloid clearance in Alzheimer's-like mice

1 reference

https://api.crossref.org/works/10.1038/S41598-020-60319-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.

1 reference

https://api.crossref.org/works/10.1038/S41598-020-60319-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I trial of a novel anti-GD2 monoclonal antibody, Hu14.18K322A, designed to decrease toxicity in children with refractory or recurrent neuroblastoma

1 reference

https://api.crossref.org/works/10.1038/S41598-020-60319-5

7 January 2021

based on heuristic

inferred from DOI database lookup

The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

1 reference

https://api.crossref.org/works/10.1038/S41598-020-60319-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease

1 reference

https://api.crossref.org/works/10.1038/S41598-020-60319-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Correlations of synaptic and pathological markers with cognition of the elderly

1 reference

https://api.crossref.org/works/10.1038/S41598-020-60319-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices

1 reference

https://api.crossref.org/works/10.1038/S41598-020-60319-5

7 January 2021

based on heuristic

inferred from DOI database lookup

T-cell epitope mapping

1 reference

https://api.crossref.org/works/10.1038/S41598-020-60319-5

7 January 2021

based on heuristic

inferred from DOI database lookup

In vitro characterization of conditions for amyloid-beta peptide oligomerization and fibrillogenesis

1 reference

https://api.crossref.org/works/10.1038/S41598-020-60319-5

7 January 2021

based on heuristic

inferred from DOI database lookup

The classical complement pathway: activation and regulation of the first complement component.

1 reference

https://pubmed.ncbi.nlm.nih.gov/32094456

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identification and removal of immunogenicity in therapeutic proteins.

1 reference

https://pubmed.ncbi.nlm.nih.gov/32094456

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014

1 reference

https://pubmed.ncbi.nlm.nih.gov/32094456

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/S41598-020-60319-5

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32094456 AND SRC:MED&resulttype=core&format=json

9 April 2020

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32094456 AND SRC:MED&resulttype=core&format=json

9 April 2020

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32094456 AND SRC:MED&resulttype=core&format=json

9 April 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q89866273&oldid=1712328408"